D'Agostino Vincenzo, Caranci Ferdinando, Negro Alberto, Piscitelli Valeria, Tuccillo Bernardino, Fasano Fabrizio, Sirabella Giovanni, Marano Ines, Granata Vincenza, Grassi Roberta, Pupo Davide, Grassi Roberto
Neuroradiology Unit, PO Ospedale del Mare, ASL NA1, via Enrico Russo, 80147 Naples, Italy.
Department of Medicine of Precision, School of Medicine, "Luigi Vanvitelli" University of Campania, 80147 Naples, Italy.
J Pers Med. 2021 Apr 8;11(4):285. doi: 10.3390/jpm11040285.
Globally, at the time of writing (20 March 2021), 121.759.109 confirmed COVID-19 cases have been reported to the WHO, including 2.690.731 deaths. Globally, on 18 March 2021, a total of 364.184.603 vaccine doses have been administered. In Italy, 3.306.711 confirmed COVID-19 cases with 103.855 deaths have been reported to WHO. In Italy, on 9 March 2021, a total of 6.634.450 vaccine doses have been administered. On 15 March 2021, Italian Medicines Agency (AIFA) decided to temporarily suspend the use of the AstraZeneca COVID-19 vaccine throughout the country as a precaution, pending the rulings of the European Medicines Agency (EMA). This decision was taken in line with similar measures adopted by other European countries due to the death of vaccinated people. On 18 March 2021, EMA's safety committee concluded its preliminary review about thromboembolic events in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting, confirming the benefits of the vaccine continue to outweigh the risk of side effects, however, the vaccine may be associated with very rare cases of blood clots associated with thrombocytopenia, i.e., low levels of blood platelets with or without bleeding, including rare cases of cerebral venous thrombosis (CVT). We report the case of a 54-year-old woman who developed disseminated intravascular coagulation (DIC) with multi-district thrombosis 12 days after the AstraZeneca COVID-19 vaccine administration. A brain computed tomography (CT) scan showed multiple subacute intra-axial hemorrhages in atypical locations, including the right frontal and the temporal lobes. A plain old balloon angioplasty (POBA) of the right coronary artery was performed, without stent implantation, with restoration of distal flow, but with persistence of extensive thrombosis of the vessel. A successive thorax angio-CT added the findings of multiple contrast filling defects with multi-vessel involvement: at the level of the left upper lobe segmental branches, of left interlobar artery, of the right middle lobe segmental branches and of the right interlobar artery. A brain magnetic resonance imaging (MRI) in the same day showed the presence of an acute basilar thrombosis associated with the superior sagittal sinus thrombosis. An abdomen angio-CT showed filling defects at the level of left portal branch and at the level of right suprahepatic vein. Bilaterally, it was adrenal hemorrhage and blood in the pelvis. An evaluation of coagulation factors did not show genetic alterations so as the nasopharyngeal swab ruled out a COVID-19 infection. The patient died after 5 days of hospitalization in intensive care.
在撰写本文时(2021年3月20日),全球已向世界卫生组织报告了121,759,109例确诊的新冠肺炎病例,其中包括2,690,731例死亡病例。在全球范围内,2021年3月18日,共接种了364,184,603剂疫苗。在意大利,已向世界卫生组织报告了3,306,711例确诊的新冠肺炎病例,其中103,855例死亡。在意大利,2021年3月9日,共接种了6,634,450剂疫苗。2021年3月15日,意大利药品管理局(AIFA)决定作为预防措施,在全国范围内暂时停用阿斯利康新冠肺炎疫苗,等待欧洲药品管理局(EMA)的裁决。由于接种疫苗者死亡,其他欧洲国家也采取了类似措施,意大利这一决定与之相符。2021年3月18日,欧洲药品管理局的安全委员会在其特别会议上完成了对接种阿斯利康新冠肺炎疫苗人群血栓栓塞事件的初步审查,确认该疫苗的益处仍大于副作用风险,然而,该疫苗可能与非常罕见的伴有血小板减少的血栓形成病例有关,即血小板水平低且有或无出血情况,包括罕见的脑静脉血栓形成(CVT)病例。我们报告了一例54岁女性的病例,该女性在接种阿斯利康新冠肺炎疫苗12天后出现弥散性血管内凝血(DIC)并伴有多部位血栓形成。脑部计算机断层扫描(CT)显示在非典型部位,包括右侧额叶和颞叶,有多处亚急性轴内出血。对右冠状动脉进行了单纯球囊血管成形术(POBA),未植入支架,远端血流得以恢复,但血管仍存在广泛血栓形成。随后的胸部血管CT检查发现多处造影剂充盈缺损,累及多支血管:左上叶段分支、左叶间动脉、右中叶段分支和右叶间动脉水平。同一天的脑部磁共振成像(MRI)显示存在与上矢状窦血栓形成相关的急性基底动脉血栓形成。腹部血管CT显示左门静脉分支和右肝静脉水平有充盈缺损。双侧均有肾上腺出血和盆腔积血。凝血因子评估未显示基因改变,鼻咽拭子检查排除了新冠肺炎感染。该患者在重症监护病房住院5天后死亡。